Palatin Technologies Inc.

ASE:PTN   3:59:50 PM EDT
-0.02 (-4.42%)

Palatin Announces Positive End-Of-Phase 2 Meeting With FDA On Pl9643 For The Treatment Of Dry Eye Disease

Published: 06/29/2021 11:44 GMT
Palatin Technologies Inc. (PTN) - Palatin Announces Positive End-of-phase 2 Meeting With FDA on Pl9643 for the Treatment of Dry Eye Disease.
Palatin Technologies - Co, FDA Reach Agreement on Path to NDA Submission, Including Trial Design, Endpoints, Interim Assessment, Patient Population.
Palatin Technologies Inc - on Track to Initiate Phase 3 Study Calendar Q4 2021 With Data Expected Calendar 2h 2022.
Palatin Technologies Inc - If Phase 3 Program Progresses As Planned, NDA Submission is Targeted for Second Half of Calendar Year 2023.